<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613322</url>
  </required_header>
  <id_info>
    <org_study_id>PHENOTECH-1</org_study_id>
    <nct_id>NCT05613322</nct_id>
  </id_info>
  <brief_title>Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia</brief_title>
  <acronym>PHENOTECH-1</acronym>
  <official_title>Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia: a Prospective, Non-interventional, Multi-centric, Clinical Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resistell AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Resistell AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the sensitivity, specificity, and accuracy of the&#xD;
      Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria&#xD;
      (i.e., E. coli or K. pneumoniae) to clinically relevant antibiotics. The study is designed as&#xD;
      a prospective, non-interventional, multi-center, single-arm study.&#xD;
&#xD;
      The blood culture samples from bacteremia patients that are positive for E. coli or K.&#xD;
      pneumoniae will be tested with the Resistell Phenotech device after strain identification by&#xD;
      MALDI-TOF. The results of the Resistell AST will be compared with the results from the disk&#xD;
      diffusion tests (all sites use the Kirby-Bauer disk diffusion test), and site dependent tests&#xD;
      (VITEK® 2, BD Phoenix™, MicroScan WalkAway system, and/or EUCAST RAST), which are currently&#xD;
      the standard AST methods in the microbiology laboratories at the participating sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2023</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the Resistell Phenotech vs Kirby-Bauer</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the sensitivity of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to the gold standard Kirby-Bauer disk diffusion test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity and accuracy of the Resistell Phenotech vs Kirby-Bauer</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the specificity and accuracy of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to the gold standard Kirby-Bauer disk diffusion test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and accuracy of the Resistell Phenotech vs other comparators</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the sensitivity, specificity, and accuracy of the Resistell Phenotech in detecting antibiotic susceptible bacteria in blood samples positive for E. coli or K. pneumoniae, compared to other routine diagnostic AST tests run at each site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to result of Resistell Phenotech vs Kirby-Bauer and other comparators</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the difference between time to result (TTR) of Resistell Phenotech and the TTR of the Kirby-Bauer and the other routine diagnostic AST methods run at each site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Category agreement and discrepancies</measure>
    <time_frame>18 months</time_frame>
    <description>To assess category agreement (CA), very major discrepancy (VMD), major discrepancy (MD) of the results obtained with Resistell Phenotech compared to the Kirby-Bauer and the other routine diagnostic AST test results at each site</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Bacteremia Sepsis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Resistell Phenotech</intervention_name>
    <description>Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bacteremia considered to be due to E. coli or K. pneumoniae.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have signed a General Consent form approving use of their residual blood&#xD;
             samples for research purposes (applicable at CHUV only)&#xD;
&#xD;
          -  Patients who have signed a consent allowing the use of their residual sample&#xD;
             (Restprobenerklärung) (applicable at MUI, only)&#xD;
&#xD;
          -  Patients over the age of 18 years (&gt;18)&#xD;
&#xD;
          -  Patients with bacteremia considered to be due to E. coli or K. pneumoniae&#xD;
&#xD;
          -  Patients whose positive blood cultures were not older than 24 hours at the time of AST&#xD;
             start&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with documented refusal of the use of biological material for research&#xD;
             purposes (applicable at CHUV, only)&#xD;
&#xD;
          -  Patients with polymicrobial bacteremia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Resistell AG</last_name>
    <phone>+41 79 899 91 88</phone>
    <email>clinops@resistell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck (MUI), Institut für Hygiene und Medizinische Mikrobiologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Lass-Flörl, Prof. Dr.</last_name>
      <email>cornelia.lass-floerl@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Cornelia Lass-Flörl, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Gstir, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Cantón, Prof. Dr.</last_name>
      <email>rafael.canton@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Rafael Cantón, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois (CHUV), Institut de Microbiologie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Greub, Prof. Dr.</last_name>
      <email>gilbert.greub@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Gilbert Greub, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>February 17, 2023</last_update_submitted>
  <last_update_submitted_qc>February 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic</keyword>
  <keyword>Susceptibility</keyword>
  <keyword>AST</keyword>
  <keyword>E.coli</keyword>
  <keyword>K. pneumoniae</keyword>
  <keyword>Phenotech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

